

# Ronac Mamtani, Msce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6351637/publications.pdf>

Version: 2024-02-01

119  
papers

5,819  
citations

168829

31  
h-index

93651

72  
g-index

123  
all docs

123  
docs citations

123  
times ranked

10645  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With <scp>Meta-Analysis</scp>. Arthritis Care and Research, 2023, 75, 260-271.	1.5	7
2	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0
3	Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone. JAMA Network Open, 2022, 5, e2142093.	2.8	16
4	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. Clinical Lung Cancer, 2022, 23, e301-e309.	1.1	2
5	Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma. Cancer, 2022, , .	2.0	0
6	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. Journal of Clinical Oncology, 2022, 40, 519-519.	0.8	0
7	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal of the National Cancer Institute, 2022, 114, 571-578.	3.0	8
8	Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. JAMA Oncology, 2022, 8, 1070.	3.4	2
9	Association between state Medicaid policies and accrual of Black participants to cancer clinical trials.. Journal of Clinical Oncology, 2022, 40, 1501-1501.	0.8	1
10	Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care.. Journal of Clinical Oncology, 2022, 40, 6527-6527.	0.8	0
11	Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2082-2092.e10.	2.4	5
12	Digoxin use is associated with pancreatic cancer risk but does not affect survival. Cancer Causes and Control, 2021, 32, 41-46.	0.8	1
13	Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 136.e11-136.e17.	0.8	3
14	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021, 371, 602-609.	6.0	784
15	Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clinical Genitourinary Cancer, 2021, 19, e17-e30.	0.9	14
16	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. Oncologist, 2021, 26, e111-e114.	1.9	1
17	Bias reduction methods for propensity scores estimated from error-prone EHR-derived covariates. Health Services and Outcomes Research Methodology, 2021, 21, 169-187.	0.8	3
18	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	1.4	26

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic <i>ATM</i> Alterations. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa121.	1.4	10
20	A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 33-38.	0.8	16
21	Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. <i>JAMA Network Open</i> , 2021, 4, e2036315.	2.8	14
22	Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. <i>Cancer</i> , 2021, 127, 2562-2570.	2.0	2
23	'Considering the totality of evidence: Combining real-world data with clinical trial results to better inform decision-making. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 814-816.	0.9	2
24	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	15.2	365
25	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , 2021, 17, e1879-e1886.	1.4	2
26	Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 121-129.	1.0	6
27	Association Between <i>KRAS</i> Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 937.	3.4	48
28	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	5.1	337
29	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. <i>JAMA Oncology</i> , 2021, 7, 1843.	3.4	26
30	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. <i>European Urology Oncology</i> , 2020, 3, 663-670.	2.6	10
31	Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2262-2268.	2.4	31
32	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. <i>Future Oncology</i> , 2020, 16, 4341-4345.	1.1	10
33	Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 575-587.	0.6	7
34	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. <i>American Heart Journal</i> , 2020, 230, 54-58.	1.2	1
35	Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018. <i>JAMA Network Open</i> , 2020, 3, e2018318.	2.8	18
36	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 967-977.	1.0	13

#	ARTICLE	IF	CITATIONS
37	Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. <i>Journal of General Internal Medicine</i> , 2020, 35, 2826-2828.	1.3	5
38	Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 599-604.	0.9	13
39	Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e1921653.	2.8	97
40	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 524-532.	0.9	38
41	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1209.	3.8	20
42	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. <i>Molecular and Clinical Oncology</i> , 2019, 10, 555-559.	0.4	2
43	Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. <i>Urology</i> , 2019, 132, 143-149.	0.5	3
44	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. <i>Cancer Medicine</i> , 2019, 8, 3698-3709.	1.3	12
45	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, 226-230.e2.	1.0	7
46	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. <i>Oncologist</i> , 2019, 24, e397-e399.	1.9	33
47	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , 2019, 24, e671-e676.	1.9	5
48	Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 318-321.	0.6	15
49	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019, 24, 688-690.	1.9	15
50	Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2019, 111, 490-497.	3.0	69
51	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 925-936.	0.9	11
52	Association between age and sex and mortality after adjuvant therapy for renal cancer. <i>Cancer</i> , 2019, 125, 1637-1644.	2.0	11
53	Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data. <i>Cancer</i> , 2019, 125, 406-415.	2.0	26
54	Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 363-369.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. <i>European Journal of Cancer</i> , 2018, 94, 1-5.	1.3	31
56	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.5	48
57	Medication class enrichment analysis: a novel algorithm to analyze multiple pharmacologic exposures simultaneously using electronic health record data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 780-789.	2.2	3
58	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-Î±-Directed Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 405-417.	0.2	99
59	Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 235-239.	0.9	7
60	Associations Between Travel Distance, Hospital Volume, and Outcomes Following Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer. <i>Urology</i> , 2018, 114, 87-94.	0.5	36
61	Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 217-226.	0.9	9
62	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classificationâ€”Defining novel predictive and prognostic markers in stage III colon cancer. <i>European Journal of Cancer</i> , 2018, 96, 105-110.	1.3	5
63	Disparities in resection of hepatic metastases in colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 126-134.	0.6	9
64	Posttraumatic Stress Disorder and Cancer Risk: A Nested Caseâ€”Control Study. <i>Journal of Traumatic Stress</i> , 2018, 31, 919-926.	1.0	5
65	Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. <i>Gastroenterology</i> , 2018, 155, 1416-1427.	0.6	19
66	Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. <i>Advances in Radiation Oncology</i> , 2018, 3, 331-338.	0.6	14
67	Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. <i>PLoS ONE</i> , 2018, 13, e0192747.	1.1	19
68	The Association between Age-Related Macular Degeneration and Renal Cell Carcinoma: A Nested Caseâ€”Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 743-747.	1.1	4
69	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. <i>Gastroenterology</i> , 2017, 152, 840-850.e3.	0.6	133
70	Neutrophilâ€”lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. <i>Cancer</i> , 2017, 123, 794-801.	2.0	51
71	Impact of metformin on the progression of MGUS to multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1265-1267.	0.6	20
72	A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 149-155.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3575-3581.	0.8	76
74	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. <i>PLoS Medicine</i> , 2016, 13, e1002007.	3.9	55
75	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. <i>Annals of Surgery</i> , 2016, 263, 298-305.	2.1	25
76	Increasing use of prescription drugs in the United Kingdom. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 628-636.	0.9	35
77	Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. <i>American Journal of Hematology</i> , 2016, 91, 581-584.	2.0	16
78	Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2403-2411.	2.9	36
79	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	0.6	120
80	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. <i>European Journal of Cancer</i> , 2016, 59, 90-98.	1.3	19
81	Parkinson's disease and colorectal cancer risk: A nested case control study. <i>Cancer Epidemiology</i> , 2016, 43, 9-14.	0.8	20
82	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2016, 23, 2936-2945.	0.7	19
83	Pernicious anemia and colorectal cancer risk: A nested case-control study. <i>Digestive and Liver Disease</i> , 2016, 48, 1386-1390.	0.4	7
84	Ion channel blockers and glioblastoma risk and outcome: a nested case-control and retrospective cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1179-1185.	0.9	1
85	An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study. <i>Archives of Dermatological Research</i> , 2016, 308, 661-664.	1.1	2
86	Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 405-412.	0.9	4
87	Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis. <i>Cancer</i> , 2016, 122, 693-701.	2.0	87
88	Liver transplant center variability in accepting organ offers and its impact on patient survival. <i>Journal of Hepatology</i> , 2016, 64, 843-851.	1.8	62
89	Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. <i>Gastroenterology</i> , 2016, 151, 120-129.e5.	0.6	145
90	Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer. <i>Journal of Urology</i> , 2016, 196, 343-348.	0.2	9

#	ARTICLE	IF	CITATIONS
91	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2076-2086.	1.1	11
92	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 164.	2.0	131
93	Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1084-1091.	1.3	15
94	Dr Lurie and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1654-e1654.	1.1	0
95	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 531-541.	2.3	18
96	Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 326-336.	0.4	15
97	The effect of past antibiotic exposure on diabetes risk. <i>European Journal of Endocrinology</i> , 2015, 172, 639-648.	1.9	131
98	The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 302-309.e11.	2.4	35
99	Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 265.	3.8	263
100	Angiosarcoma of the Bladder Following Prostate Radiotherapy. <i>American Journal of Medicine</i> , 2015, 128, e11-e12.	0.6	7
101	Thyroid Dysfunction, Thyroid Hormone Replacement and Colorectal Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv084.	3.0	46
102	Impact of antibiotic exposure on the risk of colorectal cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 534-542.	0.9	73
103	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 303-307.	1.1	15
104	Anti-depressant therapy and cancer risk: A nested case-control study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1147-1157.	0.3	21
105	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 863-872.	0.7	15
106	Recurrent antibiotic exposure may promote cancer formation “ Another step in understanding the role of the human microbiota?. <i>European Journal of Cancer</i> , 2015, 51, 2655-2664.	1.3	233
107	Antibiotic Exposure and the Risk for Depression, Anxiety, or Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1522-1528.	1.1	169
108	Digoxin use and the risk for colorectal cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1147-1153.	0.9	17

#	ARTICLE	IF	CITATIONS
109	Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 636-645.	0.9	26
110	Distinguishing incident and prevalent diabetes in an electronic medical records database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 111-118.	0.9	23
111	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <sc>N</sc>ational <sc>C</sc>ancer <sc>D</sc>ata <sc>B</sc>ase. <i>Cancer</i> , 2014, 120, 2855-2865.	2.0	54
112	Height as an independent anthropomorphic risk factor for colorectal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1422-1427.	0.8	8
113	Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. <i>Diabetes Care</i> , 2014, 37, 1910-1917.	4.3	64
114	Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1411-1421.	3.0	105
115	Granulomatosis and Testicular Germ Cell Tumors. <i>Urology</i> , 2012, 80, 1303-1306.	0.5	6
116	Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1503-1503.	0.8	3
117	Vinflunine in the treatment of advanced bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 13-20.	1.1	11
118	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829
119	Ayurveda and yoga in cardiovascular diseases. <i>Cardiology in Review</i> , 2005, 13, 155-62.	0.6	8